counter-ion is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-12. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was first isolated from human plasma by the biochemist Loren Pickart in 1973. Early work identified it as a factor that altered the behavior of cultured liver cells, and later studies linked it to connective tissue and wound-related processes. Reported plasma concentrations fall markedly between roughly age twenty and age sixty, a pattern that generated interest in copper peptide biology. Whether that decline has functional consequences remains an open question, because differences observed across age groups do not by themselves establish causation. Research interest later expanded into cosmetic and tissue-culture settings.
Mechanistic accounts focus on how the complex delivers copper and how the released peptide interacts with the extracellular matrix. Copper is an essential cofactor for lysyl oxidase and other enzymes involved in collagen and elastin cross-linking, and GHK is one of several peptides able to carry the metal. Reported effects include altered gene expression in fibroblasts and changes in matrix metalloproteinase activity, although many of these findings come from cell culture rather than whole organisms. The relative contribution of the peptide backbone, the copper ion, and downstream copper metabolism is not fully resolved.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-lysine and a copper(II) ion. The peptide sequence is conventionally written as Gly-His-Lys, abbreviated GHK. Copper binds through the imidazole nitrogen of histidine, the alpha-amino group, and a deprotonated amide nitrogen, producing a square-planar geometry. The complex carries a net positive charge near physiological pH and is intensely blue in aqueous solution. The metal-free peptide is often written simply as GHK, while the copper-bound form is written GHK-Cu.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22CuN6O4 as the complex | Free peptide is C14H24N6O4 |
| Molecular weight | About 402 g/mol | Free peptide is about 340 g/mol |
| Appearance | Blue solid or blue solution | Color from copper d-d transitions |
| Solubility class | Water-soluble; poor in nonpolar solvents | Ionic character favors aqueous media |
| Common synonyms | Copper tripeptide-1; glycyl-L-histidyl-L-lysine copper | INCI listing uses copper tripeptide-1 |
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Solutions of GHK-Cu respond strongly to pH, redox conditions, and the presence of competing chelators such as EDTA. Below roughly pH 4 the copper tends to dissociate, because the amide nitrogen donors become protonated and can no longer coordinate. Strongly alkaline conditions instead favour hydrolysis and precipitation of copper hydroxide. Dissolved oxygen and light accelerate breakdown of the peptide backbone, and the copper released during that process can catalyse further oxidation, so dry, cold, dark storage is the usual recommendation.
Routine characterisation relies on reversed-phase high-performance liquid chromatography for peptide purity, paired with mass spectrometry for identity confirmation. Ultraviolet-visible spectroscopy detects the metal centre through its absorption band in the visible region, and inductively coupled plasma mass spectrometry quantifies total copper so that a metal-to-peptide ratio can be calculated. Amino acid analysis confirms the expected residue composition. Together these techniques establish concentration, identity, and stoichiometry, but none of them directly reports biological activity.
== Mechanism == Pulsatile insulin secretion from individual beta cells is driven by oscillation of the calcium concentration in the cells. In beta cells lacking contact, the periodicity of these oscillations is rather variable (2-10 min). However, within an islet of Langerhans the oscillations become synchronized by electrical coupling between closely located beta cells that are connected by gap junctions, and the periodicity is more uniform (3-6 min).
=== 2010–2012: Early career === Melksham was recruited by the Essendon Football Club with their first selection and tenth overall in the 2009 national draft. The Age journalist, Will Brodie, predicted he would debut and play in the midfield early in the season and he made his debut in the twenty point win against Carlton at the Melbourne Cricket Ground in round three. He played the next two matches before he was omitted for the round six match against Hawthorn at the Melbourne Cricket Ground; he returned the next week for the three-point loss against Port Adelaide at Etihad Stadium where he kicked his first AFL goal. He was rewarded with the round eight nomination in the AFL Rising Star after he recorded fourteen possessions, three clearances, three tackles and a goal in the twelve point win against St Kilda at Etihad Stadium. He missed the round ten match against the Western Bulldogs after he sprained his ankle during the thirty-five-point win against Richmond the week before, he returned the next week for the nine-point loss against Sydney at the Sydney Cricket Ground. He played the next four out of five matches, missing the round fifteen match against Melbourne due to being rested, before he was dropped for the round seventeen match against North Melbourne at Etihad Stadium.
=== Economics === In February 1996, the FDA approved both the over-the-counter sale and the production of generic formulations of minoxidil. Upjohn replied to that by lowering prices to half the price of the prescription drug and by releasing a prescription 5% formula of Rogaine in 1997. In 1998, a 5% formulation of minoxidil was approved for nonprescription sale by the FDA. The 5% aerosol foam formula was approved for medical use in the US in 2006. The generic versions of the 5% aerosol foam formula were approved in 2017. In 2017, a study of pharmacy prices in four states for 41 over-the-counter minoxidil products which were "gender-specified" found that the mean price for minoxidil solutions was the same for women and men even though the women's formulations were 2% and the men's were 5%, while the mean price for minoxidil foams, which were all 5%, was 40% higher for women. The authors noted this was the first time gender-based pricing had been shown for a medication.
=== Submarine === The use of the term "submarine" or "sub" (after the resemblance of the roll to the shape of a submarine) is widespread in the United States and Canada. Some accounts source the name as originating in New London, Connecticut (near the site of a United States Navy submarine base from 1915 onwards) in the World War II era. Written advertisements from 1940 in Wilmington, Delaware, indicate the term originated prior to the United States entering World War II.
The conductivity of PEDOT:PSS can also be significantly improved by a post-treatment with various compounds, such as ethylene glycol, dimethyl sulfoxide (DMSO), salts, zwitterions, cosolvents, acids, alcohols, phenol, geminal diols and amphiphilic fluoro-compounds. This conductivity is comparable to that of ITO, the popular transparent electrode material, and it can triple that of ITO after a network of carbon nanotubes and silver nanowires is embedded into PEDOT:PSS and used for flexible organic devices. PEDOT:PSS is generally applied as a dispersion of gelled particles in water. A conductive layer on glass is obtained by spreading a layer of the dispersion on the surface usually by spin coating and driving out the water by heat. Special PEDOT:PSS inks and formulations were developed for different coating and printing processes. Water-based PEDOT:PSS inks are mainly used in slot die coating, flexography, rotogravure and inkjet printing. If a high viscous paste and slow drying is required like in screen-printing processes PEDOT:PSS can also be supplied in high boiling solvents like propanediol. Dry PEDOT:PSS pellets can be produced with a freeze drying method which are redispersable in water and different solvents, for example ethanol to increase drying speed during printing. Finally, to overcome degradation to ultraviolet light and high temperature or humidity conditions PEDOT:PSS UV-stabilizers are available. Linköping University claim to have made a "wooden transistor" by replacing the lignin from balsawood with PEDOT:PSS
Sources: en.wikipedia.org
===== MeSH D08.811.682.690 – oxygenases ===== MeSH D08.811.682.690.416 – dioxygenases MeSH D08.811.682.690.416.277 – catechol 1,2-dioxygenase MeSH D08.811.682.690.416.305 – catechol 2,3-dioxygenase MeSH D08.811.682.690.416.319 – cysteine dioxygenase MeSH D08.811.682.690.416.326 – homogentisate 1,2-dioxygenase MeSH D08.811.682.690.416.328 – 3-hydroxyanthranilate 3,4-dioxygenase MeSH D08.811.682.690.416.330 – 4-hydroxyphenylpyruvate dioxygenase MeSH D08.811.682.690.416.333 – indoleamine-pyrrole 2,3-dioxygenase MeSH D08.811.682.690.416.444 – lipoxygenase MeSH D08.811.682.690.416.444.050 – arachidonate lipoxygenases MeSH D08.811.682.690.416.444.050.055 – arachidonate 5-lipoxygenase MeSH D08.811.682.690.416.444.050.060 – arachidonate 12-lipoxygenase MeSH D08.811.682.690.416.444.050.065 – arachidonate 15-lipoxygenase MeSH D08.811.682.690.416.444.525 – protocatechuate 3,4-dioxygenase MeSH D08.811.682.690.416.722 – tryptophan oxygenase MeSH D08.811.682.690.562 – inositol oxygenase MeSH D08.811.682.690.708 – mixed function oxygenases MeSH D08.811.682.690.708.062 – benzoate 4-monooxygenase MeSH D08.811.682.690.708.125 – catechol oxidase MeSH D08.811.682.690.708.125.500 – monophenol monooxygenase MeSH D08.811.682.690.708.170 – cytochrome p-450 enzyme system MeSH D08.811.682.690.708.170.040 – aryl hydrocarbon hydroxylases MeSH D08.811.682.690.708.170.040.024 – 7-alkoxycoumarin o-dealkylase MeSH D08.811.682.690.708.170.040.050 – aniline hydroxylase MeSH D08.811.682.690.708.170.040.110 – benzopyrene hydroxylase MeSH D08.811.682.690.708.170.040.332 – cytochrome p-450 cyp1a1 MeSH D08.811.682.690.708.170.040.443 – cytochrome p-450 cyp1a2 MeSH D08.811.682.690.708.170.040.499 – cytochrome p-450 cyp2b1 MeSH D08.811.682.690.708.170.040.555 – cytochrome p-450 cyp2d6 MeSH D08.811.682.690.708.170.040.777 – cytochrome p-450 cyp2e1 MeSH D08.811.682.690.708.170.040.888 – cytochrome p-450 cyp3a MeSH D08.811.682.690.708.170.085 – camphor 5-monooxygenase MeSH D08.811.682.690.708.170.500 – alkane 1-monooxygenase MeSH D08.811.682.690.708.170.915 – steroid hydroxylases MeSH D08.811.682.690.708.170.915.050 – aldosterone synthase MeSH D08.811.682.690.708.170.915.099 – aromatase MeSH D08.811.682.690.708.170.915.200 – cholesterol 7 alpha-hydroxylase MeSH D08.811.682.690.708.170.915.212 – cholesterol side-chain cleavage enzyme MeSH D08.811.682.690.708.170.915.400 – 25-hydroxyvitamin d3 1-alpha-hydroxylase MeSH D08.811.682.690.708.170.915.720 – steroid 11-beta-hydroxylase MeSH D08.811.682.690.708.170.915.730 – steroid 12-alpha-hydroxylase MeSH D08.811.682.690.708.170.915.737 – steroid 16-alpha-hydroxylase MeSH D08.811.682.690.708.170.915.748 – steroid 17-alpha-hydroxylase MeSH D08.811.682.690.708.170.915.760 – steroid 21-hydroxylase MeSH D08.811.682.690.708.292 – dopamine beta-hydroxylase MeSH D08.811.682.690.708.392 – fatty acid desaturases MeSH D08.811.682.690.708.392.312 – beta-carotene 15,15'-monooxygenase MeSH D08.811.682.690.708.392.468 – Linoleoyl-CoA desaturase MeSH D08.811.682.690.708.392.625 – stearoyl-coa desaturase MeSH D08.811.682.690.708.401 – gamma-butyrobetaine dioxygenase MeSH D08.811.682.690.708.410 – heme oxygenase (decyclizing) MeSH D08.811.682.690.708.410.500 – heme oxygenase-1 MeSH D08.811.682.690.708.425 – 4-hydroxybenzoate 3-monooxygenase MeSH D08.811.682.690.708.557 – kynurenine 3-monooxygenase MeSH D08.811.682.690.708.601 – phenylalanine hydroxylase MeSH D08.811.682.690.708.660 – procollagen-lysine, 2-oxoglutarate 5-dioxygenase MeSH D08.811.682.690.708.673 – procollagen-proline dioxygenase MeSH D08.811.682.690.708.715 – prostaglandin-endoperoxide synthases MeSH D08.811.682.690.708.749 – squalene monooxygenase MeSH D08.811.682.690.708.783 – steroid hydroxylases MeSH D08.811.682.690.708.783.050 – aldosterone synthase MeSH D08.811.682.690.708.783.099 – aromatase MeSH D08.811.682.690.708.783.200 – cholesterol 7 alpha-hydroxylase MeSH D08.811.682.690.708.783.212 – cholesterol side-chain cleavage enzyme MeSH D08.811.682.690.708.783.400 – 25-hydroxyvitamin d3 1-alpha-hydroxylase MeSH D08.811.682.690.708.783.720 – steroid 11-beta-hydroxylase MeSH D08.811.682.690.708.783.730 – steroid 12-alpha-hydroxylase MeSH D08.811.682.690.708.783.737 – steroid 16-alpha-hydroxylase MeSH D08.811.682.690.708.783.745 – steroid 17-alpha-hydroxylase MeSH D08.811.682.690.708.783.760 – steroid 21-hydroxylase MeSH D08.811.682.690.708.826 – trans-cinnamate 4-monooxygenase MeSH D08.811.682.690.708.870 – tryptophan hydroxylase MeSH D08.811.682.690.708.923 – tyrosine 3-monooxygenase
=== Multidisciplinary doctoral programme === Has been instituted for students who have completed masters in any relevant discipline of natural sciences, medicine, engineering and other related sciences. RCB recruits Junior Research Fellowships (JRFs) twice during an academic year and already mentors 31 Research Fellows.
John Neely Kennedy (born November 21, 1951) is an American politician and attorney who has served as the junior United States senator from Louisiana since 2017. A member of the Republican Party, he served as the Louisiana State Treasurer from 2000 to 2017, as Secretary of the Louisiana Department of Revenue from 1996 to 1999, and as special counsel and then cabinet member to Governor Buddy Roemer from 1988 to 1992. Born in Centreville, Mississippi, Kennedy graduated from Vanderbilt University and the University of Virginia School of Law, and earned a law degree from the University of Oxford. In 1988, Governor Buddy Roemer selected Kennedy to serve as special legal counsel and later appointed him Secretary of the Cabinet. He left Roemer's staff in 1991 to run for state attorney general as a Democrat. In 1999, he was elected state treasurer; he was reelected in 2003, 2007, 2011, and 2015. Kennedy ran for U.S. Senate in 2004 and 2008. In August 2007, he became a Republican. In 2016, when U.S. senator David Vitter opted not to seek reelection, Kennedy ran for Senate again. He finished first in the November nonpartisan blanket primary and defeated State Public Service Commissioner Foster Campbell in the December runoff. He was sworn in on January 3, 2017. Kennedy was one of six Republican senators to object to the certification of Arizona's electors in the 2020 presidential election. In 2022, he was reelected to the Senate. Kennedy is set to be Louisiana's senior senator when Bill Cassidy leaves office in 2027.
=== Amino acid transport deficiency and neurotransmitter synthesis impairment === Amino acid transport deficiency and neurotransmitter synthesis impairment are significant concerns in individuals with maple syrup urine disease. Reduced levels of amino acids such as glutamate, phenylalanine, tyrosine, tryptophan, methionine, and alanine in the central nervous system have been shown to affect learning, memory, emotional behavior (including major depressive and anxiety disorders), ADHD, OCD, and movement disorders In a normal physiological state, large neutral amino acids (LNAA) are transferred from the blood to the brain via the large amino acid transporter (LAT1/SLC7A5) at the blood-brain barrier. However, increased plasma levels and higher affinity of leucine may saturate LAT1, thereby competitively preventing the transportation of other amino acids, resulting in lower concentrations within the brain. Amino acids such as isoleucine, valine, threonine, methionine, glutamine, tyrosine, phenylalanine, tryptophan, and histidine are particularly affected. Methionine, a precursor for S-adenosylmethionine, is essential for one-carbon metabolism in the brain, while other LAT1-transported amino acids are involved in the synthesis of neurotransmitters, including histamine, serotonin, dopamine, and norepinephrine. Increased plasma concentrations of branched-chain keto acids (BCKA) are transported through the blood–brain barrier via the monocarboxylate transporter (MCT/SLC16A1). Elevated levels of alpha-ketoisocaproate (α-KIC) result in a reduction in glutamate, glutamine, and GABA.
Sources: en.wikipedia.org
It is the copper(II) complex of the tripeptide glycyl-L-histidyl-lysine, a sequence of three amino acids. The copper ion is held by the histidine imidazole, the terminal amino group, and an amide nitrogen. The bound form is distinct from the free peptide in charge, color, and stability.
Copper(II) complexes absorb light in the red part of the visible spectrum, so transmitted light appears blue. The absorption arises from electronic transitions within the copper d-orbitals, which are split by the surrounding ligands. The intensity and exact wavelength shift somewhat with pH, solvent, and ligand arrangement.
The free peptide and the copper-bound complex are studied as separate species and do not always behave the same way in assays. Some reported responses are attributed to copper delivery, while others are attributed to the peptide sequence itself. Which fraction drives a given observation is often unresolved in the published work.
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.